REGENXBIO Inc. (RGNX) 10-Year Financial Performance & Capital Metrics

RGNX • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutREGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.Show more

Revenue $83M -7.7%
EBITDA -$217M +13.4%
Net Income -$227M +13.8%
EPS (Diluted) -4.59 +23.8%
Gross Margin 59.72% +1.6%
EBITDA Margin -260.57% +6.2%
Operating Margin -280.03% +5.8%
Net Margin -272.54% +6.7%
ROE -79.49% -24.9%
ROIC -53.79% -17.8%
Debt/Equity 0.32 +10.3%
Interest Coverage -18.43 +52.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 89 (top 11%)
✓Strong 5Y sales CAGR of 18.8%

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 13.2% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y29.84%

5Y18.79%

3Y-43.84%

TTM91.3%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM25.5%

EPS CAGR

10Y-

5Y-

3Y-

TTM31.01%

ROCE

10Y Avg-24.3%

5Y Avg-27.56%

3Y Avg-45.27%

Latest-57.87%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	7.59M	4.59M	10.39M	218.5M	35.23M	154.57M	470.35M	112.72M	90.24M	83.33M
Revenue Growth %	0.24%	-0.4%	1.26%	20.02%	-0.84%	3.39%	2.04%	-0.76%	-0.2%	-0.08%
Cost of Goods Sold+	1.5M	959K	1.71M	9.64M	8.24M	35.71M	51.83M	54.55M	37.21M	33.57M
COGS % of Revenue	0.2%	0.21%	0.16%	0.04%	0.23%	0.23%	0.11%	0.48%	0.41%	0.4%
Gross Profit+	6.08M	3.63M	8.68M	208.87M	26.99M	118.85M	418.51M	58.18M	53.03M	49.76M
Gross Margin %	0.8%	0.79%	0.84%	0.96%	0.77%	0.77%	0.89%	0.52%	0.59%	0.6%
Gross Profit Growth %	0.19%	-0.4%	1.39%	23.05%	-0.87%	3.4%	2.52%	-0.86%	-0.09%	-0.06%
Operating Expenses+	29.16M	68.97M	84.57M	120.77M	175.99M	238.09M	258.53M	321.06M	321.16M	283.11M
OpEx % of Revenue	3.84%	15.03%	8.14%	0.55%	5%	1.54%	0.55%	2.85%	3.56%	3.4%
Selling, General & Admin	11.91M	23.59M	27.23M	36.85M	51.81M	63.82M	79.33M	85.28M	88.49M	76.62M
SG&A % of Revenue	1.57%	5.14%	2.62%	0.17%	1.47%	0.41%	0.17%	0.76%	0.98%	0.92%
Research & Development	17.28M	45.48M	57.22M	83.87M	124.19M	166.29M	181.44M	242.45M	232.27M	208.52M
R&D % of Revenue	2.28%	9.91%	5.51%	0.38%	3.52%	1.08%	0.39%	2.15%	2.57%	2.5%
Other Operating Expenses	-26K	-102K	116K	42K	-10K	7.97M	-2.24M	-6.68M	397K	-2.03M
Operating Income+	-23.14M	-65.34M	-75.89M	88.1M	-149M	-119.23M	159.98M	-262.88M	-268.13M	-233.35M
Operating Margin %	-3.05%	-14.24%	-7.3%	0.4%	-4.23%	-0.77%	0.34%	-2.33%	-2.97%	-2.8%
Operating Income Growth %	-5.28%	-1.82%	-0.16%	2.16%	-2.69%	0.2%	2.34%	-2.64%	-0.02%	0.13%
EBITDA+	-23.06M	-64.8M	-73.2M	92.08M	-141.85M	-110.83M	169.54M	-249.97M	-250.81M	-217.13M
EBITDA Margin %	-3.04%	-14.12%	-7.04%	0.42%	-4.03%	-0.72%	0.36%	-2.22%	-2.78%	-2.61%
EBITDA Growth %	-5.31%	-1.81%	-0.13%	2.26%	-2.54%	0.22%	2.53%	-2.47%	-0%	0.13%
D&A (Non-Cash Add-back)	80K	544K	2.69M	3.98M	7.15M	8.41M	9.56M	12.91M	17.32M	16.21M
EBIT	-22.79M	-65.34M	-75.89M	88.1M	-97.49M	-105.24M	159.98M	-257.15M	-256.78M	-214.44M
Net Interest Income+	-20K	0	0	8.95M	2.95M	3.5M	-25.56M	-22.91M	-6.84M	-12.48M
Interest Income	0	0	0	8.95M	2.95M	4.27M	719K	342K	25K	174K
Interest Expense	20K	0	0	0	0	771K	26.28M	23.25M	6.86M	12.66M
Other Income/Expense	326K	1.94M	2.72M	16.02M	51.51M	13.22M	-18.73M	-17.53M	4.48M	6.24M
Pretax Income+	-22.81M	-63.4M	-73.17M	104.12M	-97.49M	-106.01M	141.25M	-280.4M	-263.65M	-227.1M
Pretax Margin %	-3.01%	-13.82%	-7.04%	0.48%	-2.77%	-0.69%	0.3%	-2.49%	-2.92%	-2.73%
Income Tax+	-60K	-435K	686K	4.18M	-2.75M	5.24M	13.41M	-84K	-152K	0
Effective Tax Rate %	1%	0.99%	1%	0.96%	0.97%	1.05%	0.91%	1%	1%	1%
Net Income+	-22.81M	-62.97M	-73.17M	99.94M	-94.73M	-111.25M	127.84M	-280.32M	-263.49M	-227.1M
Net Margin %	-3.01%	-13.72%	-7.04%	0.46%	-2.69%	-0.72%	0.27%	-2.49%	-2.92%	-2.73%
Net Income Growth %	-4.7%	-1.76%	-0.16%	2.37%	-1.95%	-0.17%	2.15%	-3.19%	0.06%	0.14%
Net Income (Continuing)	-22.81M	-62.97M	-73.17M	99.94M	-94.73M	-111.25M	127.84M	-280.32M	-263.49M	-227.1M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.49	-2.38	-2.45	2.73	-2.58	-2.98	2.91	-6.50	-6.02	-4.59
EPS Growth %	-7.3%	0.04%	-0.03%	2.11%	-1.95%	-0.16%	1.98%	-3.23%	0.07%	0.24%
EPS (Basic)	-2.49	-2.38	-2.45	2.73	-2.58	-2.98	3.01	-6.50	-6.02	-4.59
Diluted Shares Outstanding	9.17M	26.41M	29.88M	36.65M	36.69M	37.28M	43.91M	43.15M	43.73M	49.51M
Basic Shares Outstanding	9.17M	26.41M	29.86M	36.61M	36.69M	37.28M	42.44M	43.15M	43.73M	49.51M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	118.15M	93.37M	168M	337.91M	345.03M	531.2M	518.83M	415.98M	334.97M	278M
Cash & Short-Term Investments	114.14M	89.55M	160.78M	319.76M	296.21M	475.74M	457.44M	364.64M	275.26M	234.69M
Cash Only	54.12M	24.84M	46.66M	75.56M	69.51M	338.43M	345.21M	96.95M	34.52M	57.53M
Short-Term Investments	60.02M	64.71M	114.12M	244.2M	226.7M	137.31M	112.23M	267.69M	240.74M	177.16M
Accounts Receivable	2.14M	1.03M	473K	8.59M	38.15M	43M	32.44M	30.29M	26.34M	21.57M
Days Sales Outstanding	102.75	82.08	16.61	14.34	395.2	101.54	25.17	98.09	106.54	94.47
Inventory	1.02M	1.77M	5.33M	5.73M	0	10.51M	0	0	0	0
Days Inventory Outstanding	247.7	675.57	1.14K	217.11	-	107.36	-	-	-	-
Other Current Assets	851K	1.01M	1.41M	3.83M	4.2M	1.95M	10.2M	7.14M	18.85M	12.68M
Total Non-Current Assets+	103.23M	79.36M	30.68M	205.9M	152.88M	176.97M	595.08M	417.29M	239M	187.99M
Property, Plant & Equipment	538K	9.32M	13.98M	28.7M	39.05M	120.28M	192.45M	206.8M	192.59M	171.31M
Fixed Asset Turnover	14.10x	0.49x	0.74x	7.61x	0.90x	1.29x	2.44x	0.55x	0.47x	0.49x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	102.53M	69.41M	15.62M	150.82M	103.78M	46.81M	391.91M	200.56M	38.87M	10.18M
Other Non-Current Assets	168K	625K	1.09M	26.38M	10.04M	9.88M	10.72M	9.93M	7.54M	6.5M
Total Assets+	221.38M	172.73M	198.68M	543.81M	497.91M	708.16M	1.11B	833.27M	573.97M	465.99M
Asset Turnover	0.03x	0.03x	0.05x	0.40x	0.07x	0.22x	0.42x	0.14x	0.16x	0.18x
Asset Growth %	62.41%	-0.22%	0.15%	1.74%	-0.08%	0.42%	0.57%	-0.25%	-0.31%	-0.19%
Total Current Liabilities+	4.34M	9.67M	14.44M	22.18M	33.68M	81.45M	130.47M	130.43M	130.27M	103.19M
Accounts Payable	1.01M	1.54M	4.83M	4.41M	6.41M	10.62M	11.39M	27.21M	22.79M	22.8M
Days Payables Outstanding	246.25	587.27	1.03K	167.05	283.86	108.56	80.19	182.1	223.49	247.9
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	127K	0	0	600K	0	449K	1000K	1000K	148K	115K
Other Current Liabilities	1.83M	4.79M	3.82M	6.95M	10.9M	51.59M	57.74M	66.67M	86.04M	51.92M
Current Ratio	27.23x	9.66x	11.64x	15.24x	10.25x	6.52x	3.98x	3.19x	2.57x	2.69x
Quick Ratio	26.99x	9.47x	11.27x	14.98x	10.25x	6.39x	3.98x	3.19x	2.57x	2.69x
Cash Conversion Cycle	104.2	170.38	123.83	64.4	-	100.34	-	-	-	-
Total Non-Current Liabilities+	233K	1.33M	1.21M	12.79M	14.04M	248.96M	219.13M	186.64M	131.96M	103.14M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	5.85M	8.87M	70.15M	84.93M	88.8M	82.22M	74.13M
Deferred Tax Liabilities	0	0	0	1.1M	0	0	0	0	0	0
Other Non-Current Liabilities	233K	1.33M	1.21M	3.6M	1.83M	175.03M	134.21M	97.84M	49.73M	29.01M
Total Liabilities	4.57M	10.99M	15.65M	34.97M	47.71M	330.41M	349.61M	317.07M	262.23M	206.34M
Total Debt+	0	0	0	5.85M	11.29M	72.65M	86.68M	94.8M	89.29M	82.03M
Net Debt	-54.12M	-24.84M	-46.66M	-69.71M	-58.22M	-265.77M	-258.53M	-2.15M	54.77M	24.51M
Debt / Equity	-	-	-	0.01x	0.03x	0.19x	0.11x	0.18x	0.29x	0.32x
Debt / EBITDA	-	-	-	0.06x	-	-	0.51x	-	-	-
Net Debt / EBITDA	-	-	-	-0.76x	-	-	-1.52x	-	-	-
Interest Coverage	-1156.85x	-	-	-	-	-154.65x	6.09x	-11.30x	-39.07x	-18.43x
Total Equity+	216.81M	161.74M	183.03M	508.85M	450.2M	377.75M	764.3M	516.2M	311.74M	259.65M
Equity Growth %	39.05%	-0.25%	0.13%	1.78%	-0.12%	-0.16%	1.02%	-0.32%	-0.4%	-0.17%
Book Value per Share	23.64	6.12	6.13	13.88	12.27	10.13	17.40	11.96	7.13	5.24
Total Shareholders' Equity	216.81M	161.74M	183.03M	508.85M	450.2M	377.75M	764.3M	516.2M	311.74M	259.65M
Common Stock	3K	3K	3K	4K	4K	4K	4K	4K	4K	5K
Retained Earnings	-51.62M	-114.59M	-187.76M	-83.02M	-177.82M	-289.07M	-161.23M	-441.55M	-705.05M	-932.15M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-719K	-33K	-715K	-720K	205K	-360K	-2.57M	-15.4M	-4.43M	-741K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-22.52M	-48.56M	-57.99M	104.65M	-107.7M	-54.06M	218.88M	-207.49M	-218.41M	-173.13M
Operating CF Margin %	-2.97%	-10.58%	-5.58%	0.48%	-3.06%	-0.35%	0.47%	-1.84%	-2.42%	-2.08%
Operating CF Growth %	-8.39%	-1.16%	-0.19%	2.8%	-2.03%	0.5%	5.05%	-1.95%	-0.05%	0.21%
Net Income	-22.81M	-62.97M	-73.17M	99.94M	-94.73M	-111.25M	127.84M	-280.32M	-263.49M	-227.1M
Depreciation & Amortization	80K	544K	2.69M	3.98M	7.15M	8.41M	9.56M	12.91M	17.32M	16.21M
Stock-Based Compensation	2.92M	7.03M	10.61M	16.64M	26.85M	31.95M	38.81M	40.79M	40.27M	38.46M
Deferred Taxes	322K	2M	1.34M	794K	-38.97M	3.84M	-1.92M	0	0	0
Other Non-Cash Items	13K	-399K	-347K	-8.93M	-2.68M	-1.23M	4.36M	5.16M	-1.61M	-6.23M
Working Capital Changes	-3.04M	5.23M	897K	-7.77M	-5.33M	14.22M	40.22M	13.98M	-10.89M	5.53M
Change in Receivables	-1.34M	1.07M	561K	-16.8M	-8.62M	-9.9M	14.12M	4.82M	3.94M	9.71M
Change in Inventory	-2.51M	2.82M	-2.2M	5.35M	2.37M	17.85M	29.3M	0	0	0
Change in Payables	590K	186K	2.62M	-218K	1.53M	3.87M	-2.3M	18.79M	-2.79M	-292K
Cash from Investing+	-163.8M	19.16M	-4.79M	-279.36M	93.56M	122.76M	-406.64M	-11.93M	190.94M	103.45M
Capital Expenditures	-522K	-8.15M	-7.16M	-13.28M	-11.72M	-26.87M	-84.17M	-30.72M	-9.96M	-2.44M
CapEx % of Revenue	0.07%	1.78%	0.69%	0.06%	0.33%	0.17%	0.18%	0.27%	0.11%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-163.28M	-225K	479K	179.71M	295.98M	149.63M	4.99M	0	0	5.78M
Cash from Financing+	239.31M	119K	84.6M	204.44M	8.38M	200.21M	195.25M	-28.84M	-34.97M	92.68M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	107K	119K	2.05M	13.88M	7.06M	198.41M	-22.96M	-30.58M	-41.67M	-39.58M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-23.04M	-56.71M	-65.15M	91.37M	-119.42M	-80.93M	134.7M	-238.21M	-228.37M	-175.56M
FCF Margin %	-3.04%	-12.36%	-6.27%	0.42%	-3.39%	-0.52%	0.29%	-2.11%	-2.53%	-2.11%
FCF Growth %	-8.6%	-1.46%	-0.15%	2.4%	-2.31%	0.32%	2.66%	-2.77%	0.04%	0.23%
FCF per Share	-2.51	-2.15	-2.18	2.49	-3.25	-2.17	3.07	-5.52	-5.22	-3.55
FCF Conversion (FCF/Net Income)	0.99x	0.77x	0.79x	1.05x	1.14x	0.49x	1.71x	0.74x	0.83x	0.76x
Interest Paid	0	0	0	0	0	0	21.64M	23.12M	0	0
Taxes Paid	0	0	0	3.44M	904K	0	6M	11.81M	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-21.61%	-33.27%	-42.45%	28.89%	-19.76%	-26.87%	22.39%	-43.78%	-63.65%	-79.49%
Return on Invested Capital (ROIC)	-21.93%	-32.71%	-41.65%	22.96%	-26.89%	-35.49%	38.85%	-38.67%	-45.67%	-53.79%
Gross Margin	80.19%	79.1%	83.56%	95.59%	76.61%	76.89%	88.98%	51.61%	58.76%	59.72%
Net Margin	-300.62%	-1372.13%	-704.02%	45.74%	-268.88%	-71.98%	27.18%	-248.68%	-291.99%	-272.54%
Debt / Equity	-	-	-	0.01x	0.03x	0.19x	0.11x	0.18x	0.29x	0.32x
Interest Coverage	-1156.85x	-	-	-	-	-154.65x	6.09x	-11.30x	-39.07x	-18.43x
FCF Conversion	0.99x	0.77x	0.79x	1.05x	1.14x	0.49x	1.71x	0.74x	0.83x	0.76x
Revenue Growth	23.99%	-39.52%	126.48%	2002.42%	-83.88%	338.7%	204.3%	-76.03%	-19.94%	-7.66%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
License and Service	-	-	-	-	112.72M	90.24M	83.33M
License and Service Growth	-	-	-	-	-	-19.94%	-7.66%
License And Service	-	-	154.57M	470.35M	-	-	-
License And Service Growth	-	-	-	204.30%	-	-	-
Zolgensma Royalties	-	20.83M	-	-	-	-	-
Zolgensma Royalties Growth	-	-	-	-	-	-	-
License	218.5M	3.5M	-	-	-	-	-
License Growth	-	-98.40%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

REGENXBIO Inc. (RGNX) reported $161.3M in revenue for fiscal year 2024. This represents a 2550% increase from $6.1M in 2013.

REGENXBIO Inc. (RGNX) saw revenue decline by 7.7% over the past year.

REGENXBIO Inc. (RGNX) reported a net loss of $177.9M for fiscal year 2024.

Dividend & Returns

REGENXBIO Inc. (RGNX) has a return on equity (ROE) of -79.5%. Negative ROE indicates the company is unprofitable.

REGENXBIO Inc. (RGNX) had negative free cash flow of $106.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

REGENXBIO Inc. (RGNX) 10-Year Financial Performance & Capital Metrics

RGNX • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $83M -7.7%
EBITDA -$217M +13.4%
Net Income -$227M +13.8%
EPS (Diluted) -4.59 +23.8%
Gross Margin 59.72% +1.6%
EBITDA Margin -260.57% +6.2%
Operating Margin -280.03% +5.8%
Net Margin -272.54% +6.7%
ROE -79.49% -24.9%
ROIC -53.79% -17.8%
Debt/Equity 0.32 +10.3%
Interest Coverage -18.43 +52.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 89 (top 11%)
✓Strong 5Y sales CAGR of 18.8%

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 13.2% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y29.84%

5Y18.79%

3Y-43.84%

TTM91.3%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM25.5%

EPS CAGR

10Y-

5Y-

3Y-

TTM31.01%

ROCE

10Y Avg-24.3%

5Y Avg-27.56%

3Y Avg-45.27%

Latest-57.87%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	7.59M	4.59M	10.39M	218.5M	35.23M	154.57M	470.35M	112.72M	90.24M	83.33M
Revenue Growth %	0.24%	-0.4%	1.26%	20.02%	-0.84%	3.39%	2.04%	-0.76%	-0.2%	-0.08%
Cost of Goods Sold+	1.5M	959K	1.71M	9.64M	8.24M	35.71M	51.83M	54.55M	37.21M	33.57M
COGS % of Revenue	0.2%	0.21%	0.16%	0.04%	0.23%	0.23%	0.11%	0.48%	0.41%	0.4%
Gross Profit+	6.08M	3.63M	8.68M	208.87M	26.99M	118.85M	418.51M	58.18M	53.03M	49.76M
Gross Margin %	0.8%	0.79%	0.84%	0.96%	0.77%	0.77%	0.89%	0.52%	0.59%	0.6%
Gross Profit Growth %	0.19%	-0.4%	1.39%	23.05%	-0.87%	3.4%	2.52%	-0.86%	-0.09%	-0.06%
Operating Expenses+	29.16M	68.97M	84.57M	120.77M	175.99M	238.09M	258.53M	321.06M	321.16M	283.11M
OpEx % of Revenue	3.84%	15.03%	8.14%	0.55%	5%	1.54%	0.55%	2.85%	3.56%	3.4%
Selling, General & Admin	11.91M	23.59M	27.23M	36.85M	51.81M	63.82M	79.33M	85.28M	88.49M	76.62M
SG&A % of Revenue	1.57%	5.14%	2.62%	0.17%	1.47%	0.41%	0.17%	0.76%	0.98%	0.92%
Research & Development	17.28M	45.48M	57.22M	83.87M	124.19M	166.29M	181.44M	242.45M	232.27M	208.52M
R&D % of Revenue	2.28%	9.91%	5.51%	0.38%	3.52%	1.08%	0.39%	2.15%	2.57%	2.5%
Other Operating Expenses	-26K	-102K	116K	42K	-10K	7.97M	-2.24M	-6.68M	397K	-2.03M
Operating Income+	-23.14M	-65.34M	-75.89M	88.1M	-149M	-119.23M	159.98M	-262.88M	-268.13M	-233.35M
Operating Margin %	-3.05%	-14.24%	-7.3%	0.4%	-4.23%	-0.77%	0.34%	-2.33%	-2.97%	-2.8%
Operating Income Growth %	-5.28%	-1.82%	-0.16%	2.16%	-2.69%	0.2%	2.34%	-2.64%	-0.02%	0.13%
EBITDA+	-23.06M	-64.8M	-73.2M	92.08M	-141.85M	-110.83M	169.54M	-249.97M	-250.81M	-217.13M
EBITDA Margin %	-3.04%	-14.12%	-7.04%	0.42%	-4.03%	-0.72%	0.36%	-2.22%	-2.78%	-2.61%
EBITDA Growth %	-5.31%	-1.81%	-0.13%	2.26%	-2.54%	0.22%	2.53%	-2.47%	-0%	0.13%
D&A (Non-Cash Add-back)	80K	544K	2.69M	3.98M	7.15M	8.41M	9.56M	12.91M	17.32M	16.21M
EBIT	-22.79M	-65.34M	-75.89M	88.1M	-97.49M	-105.24M	159.98M	-257.15M	-256.78M	-214.44M
Net Interest Income+	-20K	0	0	8.95M	2.95M	3.5M	-25.56M	-22.91M	-6.84M	-12.48M
Interest Income	0	0	0	8.95M	2.95M	4.27M	719K	342K	25K	174K
Interest Expense	20K	0	0	0	0	771K	26.28M	23.25M	6.86M	12.66M
Other Income/Expense	326K	1.94M	2.72M	16.02M	51.51M	13.22M	-18.73M	-17.53M	4.48M	6.24M
Pretax Income+	-22.81M	-63.4M	-73.17M	104.12M	-97.49M	-106.01M	141.25M	-280.4M	-263.65M	-227.1M
Pretax Margin %	-3.01%	-13.82%	-7.04%	0.48%	-2.77%	-0.69%	0.3%	-2.49%	-2.92%	-2.73%
Income Tax+	-60K	-435K	686K	4.18M	-2.75M	5.24M	13.41M	-84K	-152K	0
Effective Tax Rate %	1%	0.99%	1%	0.96%	0.97%	1.05%	0.91%	1%	1%	1%
Net Income+	-22.81M	-62.97M	-73.17M	99.94M	-94.73M	-111.25M	127.84M	-280.32M	-263.49M	-227.1M
Net Margin %	-3.01%	-13.72%	-7.04%	0.46%	-2.69%	-0.72%	0.27%	-2.49%	-2.92%	-2.73%
Net Income Growth %	-4.7%	-1.76%	-0.16%	2.37%	-1.95%	-0.17%	2.15%	-3.19%	0.06%	0.14%
Net Income (Continuing)	-22.81M	-62.97M	-73.17M	99.94M	-94.73M	-111.25M	127.84M	-280.32M	-263.49M	-227.1M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.49	-2.38	-2.45	2.73	-2.58	-2.98	2.91	-6.50	-6.02	-4.59
EPS Growth %	-7.3%	0.04%	-0.03%	2.11%	-1.95%	-0.16%	1.98%	-3.23%	0.07%	0.24%
EPS (Basic)	-2.49	-2.38	-2.45	2.73	-2.58	-2.98	3.01	-6.50	-6.02	-4.59
Diluted Shares Outstanding	9.17M	26.41M	29.88M	36.65M	36.69M	37.28M	43.91M	43.15M	43.73M	49.51M
Basic Shares Outstanding	9.17M	26.41M	29.86M	36.61M	36.69M	37.28M	42.44M	43.15M	43.73M	49.51M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	118.15M	93.37M	168M	337.91M	345.03M	531.2M	518.83M	415.98M	334.97M	278M
Cash & Short-Term Investments	114.14M	89.55M	160.78M	319.76M	296.21M	475.74M	457.44M	364.64M	275.26M	234.69M
Cash Only	54.12M	24.84M	46.66M	75.56M	69.51M	338.43M	345.21M	96.95M	34.52M	57.53M
Short-Term Investments	60.02M	64.71M	114.12M	244.2M	226.7M	137.31M	112.23M	267.69M	240.74M	177.16M
Accounts Receivable	2.14M	1.03M	473K	8.59M	38.15M	43M	32.44M	30.29M	26.34M	21.57M
Days Sales Outstanding	102.75	82.08	16.61	14.34	395.2	101.54	25.17	98.09	106.54	94.47
Inventory	1.02M	1.77M	5.33M	5.73M	0	10.51M	0	0	0	0
Days Inventory Outstanding	247.7	675.57	1.14K	217.11	-	107.36	-	-	-	-
Other Current Assets	851K	1.01M	1.41M	3.83M	4.2M	1.95M	10.2M	7.14M	18.85M	12.68M
Total Non-Current Assets+	103.23M	79.36M	30.68M	205.9M	152.88M	176.97M	595.08M	417.29M	239M	187.99M
Property, Plant & Equipment	538K	9.32M	13.98M	28.7M	39.05M	120.28M	192.45M	206.8M	192.59M	171.31M
Fixed Asset Turnover	14.10x	0.49x	0.74x	7.61x	0.90x	1.29x	2.44x	0.55x	0.47x	0.49x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	102.53M	69.41M	15.62M	150.82M	103.78M	46.81M	391.91M	200.56M	38.87M	10.18M
Other Non-Current Assets	168K	625K	1.09M	26.38M	10.04M	9.88M	10.72M	9.93M	7.54M	6.5M
Total Assets+	221.38M	172.73M	198.68M	543.81M	497.91M	708.16M	1.11B	833.27M	573.97M	465.99M
Asset Turnover	0.03x	0.03x	0.05x	0.40x	0.07x	0.22x	0.42x	0.14x	0.16x	0.18x
Asset Growth %	62.41%	-0.22%	0.15%	1.74%	-0.08%	0.42%	0.57%	-0.25%	-0.31%	-0.19%
Total Current Liabilities+	4.34M	9.67M	14.44M	22.18M	33.68M	81.45M	130.47M	130.43M	130.27M	103.19M
Accounts Payable	1.01M	1.54M	4.83M	4.41M	6.41M	10.62M	11.39M	27.21M	22.79M	22.8M
Days Payables Outstanding	246.25	587.27	1.03K	167.05	283.86	108.56	80.19	182.1	223.49	247.9
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	127K	0	0	600K	0	449K	1000K	1000K	148K	115K
Other Current Liabilities	1.83M	4.79M	3.82M	6.95M	10.9M	51.59M	57.74M	66.67M	86.04M	51.92M
Current Ratio	27.23x	9.66x	11.64x	15.24x	10.25x	6.52x	3.98x	3.19x	2.57x	2.69x
Quick Ratio	26.99x	9.47x	11.27x	14.98x	10.25x	6.39x	3.98x	3.19x	2.57x	2.69x
Cash Conversion Cycle	104.2	170.38	123.83	64.4	-	100.34	-	-	-	-
Total Non-Current Liabilities+	233K	1.33M	1.21M	12.79M	14.04M	248.96M	219.13M	186.64M	131.96M	103.14M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	5.85M	8.87M	70.15M	84.93M	88.8M	82.22M	74.13M
Deferred Tax Liabilities	0	0	0	1.1M	0	0	0	0	0	0
Other Non-Current Liabilities	233K	1.33M	1.21M	3.6M	1.83M	175.03M	134.21M	97.84M	49.73M	29.01M
Total Liabilities	4.57M	10.99M	15.65M	34.97M	47.71M	330.41M	349.61M	317.07M	262.23M	206.34M
Total Debt+	0	0	0	5.85M	11.29M	72.65M	86.68M	94.8M	89.29M	82.03M
Net Debt	-54.12M	-24.84M	-46.66M	-69.71M	-58.22M	-265.77M	-258.53M	-2.15M	54.77M	24.51M
Debt / Equity	-	-	-	0.01x	0.03x	0.19x	0.11x	0.18x	0.29x	0.32x
Debt / EBITDA	-	-	-	0.06x	-	-	0.51x	-	-	-
Net Debt / EBITDA	-	-	-	-0.76x	-	-	-1.52x	-	-	-
Interest Coverage	-1156.85x	-	-	-	-	-154.65x	6.09x	-11.30x	-39.07x	-18.43x
Total Equity+	216.81M	161.74M	183.03M	508.85M	450.2M	377.75M	764.3M	516.2M	311.74M	259.65M
Equity Growth %	39.05%	-0.25%	0.13%	1.78%	-0.12%	-0.16%	1.02%	-0.32%	-0.4%	-0.17%
Book Value per Share	23.64	6.12	6.13	13.88	12.27	10.13	17.40	11.96	7.13	5.24
Total Shareholders' Equity	216.81M	161.74M	183.03M	508.85M	450.2M	377.75M	764.3M	516.2M	311.74M	259.65M
Common Stock	3K	3K	3K	4K	4K	4K	4K	4K	4K	5K
Retained Earnings	-51.62M	-114.59M	-187.76M	-83.02M	-177.82M	-289.07M	-161.23M	-441.55M	-705.05M	-932.15M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-719K	-33K	-715K	-720K	205K	-360K	-2.57M	-15.4M	-4.43M	-741K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-22.52M	-48.56M	-57.99M	104.65M	-107.7M	-54.06M	218.88M	-207.49M	-218.41M	-173.13M
Operating CF Margin %	-2.97%	-10.58%	-5.58%	0.48%	-3.06%	-0.35%	0.47%	-1.84%	-2.42%	-2.08%
Operating CF Growth %	-8.39%	-1.16%	-0.19%	2.8%	-2.03%	0.5%	5.05%	-1.95%	-0.05%	0.21%
Net Income	-22.81M	-62.97M	-73.17M	99.94M	-94.73M	-111.25M	127.84M	-280.32M	-263.49M	-227.1M
Depreciation & Amortization	80K	544K	2.69M	3.98M	7.15M	8.41M	9.56M	12.91M	17.32M	16.21M
Stock-Based Compensation	2.92M	7.03M	10.61M	16.64M	26.85M	31.95M	38.81M	40.79M	40.27M	38.46M
Deferred Taxes	322K	2M	1.34M	794K	-38.97M	3.84M	-1.92M	0	0	0
Other Non-Cash Items	13K	-399K	-347K	-8.93M	-2.68M	-1.23M	4.36M	5.16M	-1.61M	-6.23M
Working Capital Changes	-3.04M	5.23M	897K	-7.77M	-5.33M	14.22M	40.22M	13.98M	-10.89M	5.53M
Change in Receivables	-1.34M	1.07M	561K	-16.8M	-8.62M	-9.9M	14.12M	4.82M	3.94M	9.71M
Change in Inventory	-2.51M	2.82M	-2.2M	5.35M	2.37M	17.85M	29.3M	0	0	0
Change in Payables	590K	186K	2.62M	-218K	1.53M	3.87M	-2.3M	18.79M	-2.79M	-292K
Cash from Investing+	-163.8M	19.16M	-4.79M	-279.36M	93.56M	122.76M	-406.64M	-11.93M	190.94M	103.45M
Capital Expenditures	-522K	-8.15M	-7.16M	-13.28M	-11.72M	-26.87M	-84.17M	-30.72M	-9.96M	-2.44M
CapEx % of Revenue	0.07%	1.78%	0.69%	0.06%	0.33%	0.17%	0.18%	0.27%	0.11%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-163.28M	-225K	479K	179.71M	295.98M	149.63M	4.99M	0	0	5.78M
Cash from Financing+	239.31M	119K	84.6M	204.44M	8.38M	200.21M	195.25M	-28.84M	-34.97M	92.68M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	107K	119K	2.05M	13.88M	7.06M	198.41M	-22.96M	-30.58M	-41.67M	-39.58M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-23.04M	-56.71M	-65.15M	91.37M	-119.42M	-80.93M	134.7M	-238.21M	-228.37M	-175.56M
FCF Margin %	-3.04%	-12.36%	-6.27%	0.42%	-3.39%	-0.52%	0.29%	-2.11%	-2.53%	-2.11%
FCF Growth %	-8.6%	-1.46%	-0.15%	2.4%	-2.31%	0.32%	2.66%	-2.77%	0.04%	0.23%
FCF per Share	-2.51	-2.15	-2.18	2.49	-3.25	-2.17	3.07	-5.52	-5.22	-3.55
FCF Conversion (FCF/Net Income)	0.99x	0.77x	0.79x	1.05x	1.14x	0.49x	1.71x	0.74x	0.83x	0.76x
Interest Paid	0	0	0	0	0	0	21.64M	23.12M	0	0
Taxes Paid	0	0	0	3.44M	904K	0	6M	11.81M	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-21.61%	-33.27%	-42.45%	28.89%	-19.76%	-26.87%	22.39%	-43.78%	-63.65%	-79.49%
Return on Invested Capital (ROIC)	-21.93%	-32.71%	-41.65%	22.96%	-26.89%	-35.49%	38.85%	-38.67%	-45.67%	-53.79%
Gross Margin	80.19%	79.1%	83.56%	95.59%	76.61%	76.89%	88.98%	51.61%	58.76%	59.72%
Net Margin	-300.62%	-1372.13%	-704.02%	45.74%	-268.88%	-71.98%	27.18%	-248.68%	-291.99%	-272.54%
Debt / Equity	-	-	-	0.01x	0.03x	0.19x	0.11x	0.18x	0.29x	0.32x
Interest Coverage	-1156.85x	-	-	-	-	-154.65x	6.09x	-11.30x	-39.07x	-18.43x
FCF Conversion	0.99x	0.77x	0.79x	1.05x	1.14x	0.49x	1.71x	0.74x	0.83x	0.76x
Revenue Growth	23.99%	-39.52%	126.48%	2002.42%	-83.88%	338.7%	204.3%	-76.03%	-19.94%	-7.66%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
License and Service	-	-	-	-	112.72M	90.24M	83.33M
License and Service Growth	-	-	-	-	-	-19.94%	-7.66%
License And Service	-	-	154.57M	470.35M	-	-	-
License And Service Growth	-	-	-	204.30%	-	-	-
Zolgensma Royalties	-	20.83M	-	-	-	-	-
Zolgensma Royalties Growth	-	-	-	-	-	-	-
License	218.5M	3.5M	-	-	-	-	-
License Growth	-	-98.40%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

REGENXBIO Inc. (RGNX) reported $161.3M in revenue for fiscal year 2024. This represents a 2550% increase from $6.1M in 2013.

REGENXBIO Inc. (RGNX) saw revenue decline by 7.7% over the past year.

REGENXBIO Inc. (RGNX) reported a net loss of $177.9M for fiscal year 2024.

Dividend & Returns

REGENXBIO Inc. (RGNX) has a return on equity (ROE) of -79.5%. Negative ROE indicates the company is unprofitable.

REGENXBIO Inc. (RGNX) had negative free cash flow of $106.3M in fiscal year 2024, likely due to heavy capital investments.